Alabama Department of Public Health
Alabama Emergency Response Technology (ALERT)
Health Alert Network (HAN)
January 27, 2023
Evusheld Not Authorized in U.S. for Current SAR-CoV-2 Subvariants

On January 26, 2023, the Food and Drug Administration (FDA) announced that Evusheld (tixagevimab co-packaged with cilgavimab) is not currently authorized for emergency use in the U.S. Based on current data, it is unlikely to be active against more that 90 percent of the SARS-CoV-2 variants currently circulating in the U.S. Therefore, it is not expected to provide protection against developing COVID-19 if exposed to these variants. HHS and AstraZeneca have paused distribution of Evusheld until further notice.

Providers are asked to continue to store any remaining Evusheld vials appropriately in case it is effective against future variants. Full information regarding this change can be found at https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us

Paxlovid, Veklury, and Lagevrio are expected to retain activity against current variants. For additional information concerning COVID 19 therapeutics, please visit links from the Clinician Outreach and Communication Activity Call, Infectious Disease Society of America, the CDC, National Institutes of Health, and ASPR.

https://emergency.cdc.gov/coca/calls/2023/callinfo_012423.asp

https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/

https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/

https://www.covid19treatmentguidelines.nih.gov/

https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx